Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

AMKL chimeric transcription factors are potent inducers of leukemia.

Leukemia·2017

Same author

Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia.

Oncogene·2016

Same author

Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy.

Leukemia·2016

Same author

Comparison of genome sequencing and clinical genotyping for pharmacogenes.

Clinical pharmacology and therapeutics·2016

Same author

A revised definition for cure of childhood acute lymphoblastic leukemia.

Leukemia·2014

Same author

Calcium and cholecalciferol supplementation provides no added benefit to nutritional counseling to improve bone mineral density in survivors of childhood acute lymphoblastic leukemia (ALL).

Pediatric blood & cancer·2014

Search research articles

Related Experiment Video

Updated: Jun 4, 2026

Semi-quantitative Detection of RNA-dependent RNA Polymerase Activity of Human Telomerase Reverse Transcriptase Protein

Semi-quantitative Detection of RNA-dependent RNA Polymerase Activity of Human Telomerase Reverse Transcriptase Protein

Published on: June 12, 2018

NPM-ALK Reverse Transcriptase-Polymerase Chain Reaction for Detecting the t(2;5) of Non-Hodgkin's Lymphoma.

S A Shurtleff¹, J R Downing, S W Morris

¹Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN.

Methods in Molecular Medicine

|February 12, 2011

Summary

Modern molecular biology aids in diagnosing non-Hodgkin's lymphoma (NHL). Specific genetic abnormalities, like BCL6 and NPM-ALK, identify large-cell lymphoma subtypes with distinct prognoses, improving patient stratification.

More Related Videos

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

Related Experiment Videos

Last Updated: Jun 4, 2026

Semi-quantitative Detection of RNA-dependent RNA Polymerase Activity of Human Telomerase Reverse Transcriptase Protein

Semi-quantitative Detection of RNA-dependent RNA Polymerase Activity of Human Telomerase Reverse Transcriptase Protein

Published on: June 12, 2018

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

Area of Science:

Oncology
Molecular Biology
Genetics

Background:

Traditional methods for diagnosing non-Hodgkin's lymphoma (NHL) using morphology and immunophenotyping have limitations, particularly in classifying large-cell lymphomas.
Large-cell lymphomas exhibit significant heterogeneity, making traditional subclassification challenging.
Molecular biology techniques offer new insights into the genetic basis of NHL.

Purpose of the Study:

To explore the utility of molecular genetic abnormalities in subcategorizing large-cell lymphomas.
To identify patient subsets within large-cell NHL based on genetic alterations.
To correlate genetic subtypes with therapeutic responses and survival rates.

Main Methods:

Analysis of genetic abnormalities in large-cell non-Hodgkin's lymphoma.
Focus on BCL6/LAZ3 gene activation at 3q27 and the NPM-ALK fusion gene resulting from t(2;5).
Correlation of identified molecular subtypes with clinical outcomes.

Main Results:

Two recurrent genetic abnormalities, BCL6/LAZ3 and NPM-ALK, were identified in large-cell NHL.
These molecular subtypes allow for the identification of patient subsets with distinct therapeutic responses and survival rates.
Cases with these specific gene abnormalities appear to have a superior prognosis compared to those without.

Conclusions:

Molecular genetic analysis, specifically identifying BCL6/LAZ3 and NPM-ALK alterations, provides a powerful tool for subcategorizing large-cell lymphomas.
This molecular subcategorization enables more accurate prognostication and potentially tailored treatment strategies for NHL patients.
Genetic profiling complements traditional diagnostic methods, leading to improved patient management in non-Hodgkin's lymphoma.